Video
Dr. Bryan Mehlhaff on Advances in mCRPC
Author(s):
Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).
Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).
Sipuleucel-T (Provenge), abiraterone acetate (Zytiga), enzalutamide (Xtandi), and radium-223 have all made a significant impact in mCRPC in recent years, says Mehlhaff.
There has been a lot of progress in mCRPC. Six to 8 years ago urologists could only give hormone therapy or used the first generation receptor blockers; there really wasn’t a lot to offer.
Today we’ve doubled the life expectancy of mCRPC, and those are quality added years, not just life extension, says Mehlhaff. There are more advances on the horizon and patients with mCRPC have a better outlook than ever before, he adds
